A cucumber extract marketed as Q-actin by IminoTech was found to support self-reported measures of joint comfort and function at a low dose of 20 mg per day in a recent clinical study published in Cureus.

Q-actin, which is standardized to a bioactive compound idoBR1, was tested against a placebo in 80 adults who reported mild-to-moderate joint pain for a 60-day treatment window. Assessments were conducted at days 15, 30, and 60 using WOMAC, Lequesne Functional Index, Brief Pain Inventory, and Pain Disability Index.

Significant improvements in assessment scores emerged by day 30 and strengthened throughout the study. By Day 60, Q-actin participants experienced a 31.79% decrease in WOMAC scores (indicating less pain and stiffness and better function), a 32.39% reduction on the Pain Disability Index (less interference with work, sleep, mood, and daily activities), and a 10.07% improvement on the Lequesne Functional Index (indicating gains in mobility and functional capacity).

“These results not only confirm Q-actin’s benefits, they extend them beyond previous osteoarthritis studies to adults with mild to moderate joint pain,” said Shil Kothari, CEO of IminoTech. “Consistent outcomes with a tiny 20 mg daily dose show Q-actin delivers reliable, everyday joint health benefits that consumers can feel.”

The findings translate beyond osteoarthritis and are relevant for product claims related to everyday joint comfort, IminoTech noted.